Loading patent…
AssigneeJanssen Vaccines & Prevention B.V.
InventorsJan Willem Meijberg, Antonietta Impagliazzo, Katarina Radosevic, Jehangir Wadia, Robert Anthony Williamson, Michelle Wagner, Zhaoqing Ding
Estimating the term…
Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment comprising the amino acids from position 1 to position x, preferably from position p to position x, of the HA1 domain, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, comprising the amino acids from position y to and including the C-terminal amino acid of the HA1 domain; and (b) an influenza hemagglutinin HA2 domain, wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction between HA1 and HA2, and wherein one or more amino acid of the amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and/or 416 have been mutated, as compared to the corresponding positions in wild-type influenza HA.
An influenza hemagglutinin (HA) stem domain polypeptide comprising the amino acid sequence of SEQ ID NO:
An influenza hemagglutinin (HA) stem domain polypeptide, wherein the polypeptide comprises a peptide having the amino acid sequence selected from the group consisting of SEQ ID NO:
An influenza hemagglutinin (HA) stem domain polypeptide, wherein the polypeptide comprises a peptide having the amino acid sequence selected from the group consisting of SEQ ID NO:
Dependencies are inferred from the claim text.